2022
Orally Administered Probiotics in the Prevention of Chemotherapy (± Radiotherapy)-Induced Gastrointestinal Toxicity: A Systematic Review With Meta-Analysis of Randomized Trials
DANIS, Radoslav, Michal MEGO, Mariya ANTONOVA, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK et. al.Základní údaje
Originální název
Orally Administered Probiotics in the Prevention of Chemotherapy (± Radiotherapy)-Induced Gastrointestinal Toxicity: A Systematic Review With Meta-Analysis of Randomized Trials
Autoři
DANIS, Radoslav (garant), Michal MEGO, Mariya ANTONOVA, Radka ŠTĚPÁNOVÁ (203 Česká republika), Adam SVOBODNÍK (203 Česká republika), Renata HEJNOVÁ (203 Česká republika, domácí) a Martin WAWRUCH
Vydání
INTEGRATIVE CANCER THERAPIES, THOUSAND OAKS, SAGE PUBLICATIONS INC, 2022, 1534-7354
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.900
Kód RIV
RIV/00216224:14110/22:00127762
Organizační jednotka
Lékařská fakulta
UT WoS
000905190300003
Klíčová slova česky
probiotics; cancer; chemotherapy; adverse effects; diarrhea; prevention
Klíčová slova anglicky
probiotics; cancer; chemotherapy; adverse effects; diarrhea; prevention
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 19. 2. 2024 11:21, Mgr. Tereza Miškechová
Anotace
V originále
Background: Chemoradiotherapy-induced gastrointestinal toxicity may lead to a significant impairment of the oncological patient’s quality of life, as well as to reduced adherence to the treatment, which may have a negative impact on survival and mortality rates. Objective: The aim of this review was to investigate whether oral probiotic administration prevents chemotherapy (± radiotherapy)-induced gastrointestinal toxicity, particularly diarrhea. Methods: We searched the MEDLINE, Web of Science, and SCOPUS databases for randomized controlled trials in English published between 1990 and 2020. We conducted statistical data analyses expressing the treatment effect size as a risk ratio (RR) together with a 95% confidence interval (CI). Implications are based on trials rated as having a low risk of bias (RoB). Results: We included 8 trials (n=697 participants), from which 3 studies rated as low RoB contained primary endpoint data; the risk of developing grade 3/4 diarrhea in patients receiving probiotics was reduced by 78% compared to the control group (RR=0.22 [95% CI 0.05-1.08]; P=.06; n=114 participants). Probiotics showed preventive effects in patients treated with chemotherapy alone (RR=0.34 [0.12-0.94]; P=.04, n=121 participants) and in patients with colorectal cancer (RR=0.56 [0.34-0.92]; P=.02; n=208 participants). The reduction in the incidence of overall diarrhea was not significant. Conclusions: Probiotics failed to prove a preventive effect of statistical significance against the development of severe and overall diarrhea in cancer patients treated with chemotherapy (± radiotherapy). However, we cannot rule out that the effects of probiotics are clinically relevant, especially in certain subgroups of patients. This needs to be clarified in further well-performed studies.
Návaznosti
CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU (Kód CEP: EF16_013/0001826) |
| ||
90128, velká výzkumná infrastruktura |
|